Neoadjuvant therapy for locally advanced rectal cancer is becoming increasingly common. However, biomarkers predicting the response to neoadjuvant therapy have not been established. Tumor-infiltrating lymphocytes (TILs) have a crucial effect on tumor progression and survival outcome as the primary host immune response, and an antitumor immune effect has been reported to contribute to the response to radiotherapy and chemotherapy. We investigated the significance of TILs before and after neoadjuvant treatment and the change in the density of those TILs. Sixtyfour patients who underwent radical resection after neoadjuvant treatment for locally advanced rectal cancer were enrolled. The number of TIL subsets was examined using immunohistochemical staining of pretreatment biopsy samples and posttreatment resected specimens. In both the neoadjuvant chemotherapy cohort and the neoadjuvant chemoradiotherapy cohort, a low density of CD8 + TILs in pretreatment biopsy samples was associated with a poor response, and a low density of CD8 + TILs in post-treatment resected specimens was similarly associated with a poor response. In the neoadjuvant chemoradiotherapy cohort, the density of CD8 + TILs in post-treatment resected specimens was significantly increased compared with that in pretreatment biopsy samples. We concluded that T lymphocytemediated immune reactions play an important role in tumor response to neoadjuvant treatment for rectal cancer, and the evaluation of TILs in pretreatment biopsy samples might be a predictor of the clinical effectiveness of neoadjuvant treatment.
order to reduce the local recurrence rate. 2 In addition, neoadjuvant
CT was proposed as a new treatment strategy in order to reduce not only the local recurrence rate but also the distant metastasis rate. 3 However, in unresponsive cases, neoadjuvant therapy could have disadvantages, such as allowing tumor progression or delaying surgery, thereby making it impossible to undertake curative surgery in such patients. Therefore, it is necessary to carry out such surgery as early as possible in unresponsive cases, which requires being able to predict a given patient's clinical response to neoadjuvant treatment. However, the biomarkers predicting the clinical response to neoadjuvant treatment have not been established.
As part of the primary host immune response to malignant tumors, TILs critically influence tumor progression and survival outcomes. [4] [5] [6] Galon et al 7 established the immunoscore as a prognostic indicator by evaluating the density of TILs and reported that the immunoscore is a more valuable prognostic indicator than traditional histopathological scores, such as the TNM classification. [7] [8] [9] [10] Furthermore, the antitumor immune response has also been reported to contribute to the response to radiotherapy and CT. [11] [12] [13] [14] However, the mechanisms underlying the correlation between antitumor immunity and the response to radiotherapy and CT have yet to be fully clarified.
In the present study, we investigated the significance of TILs in pretreatment biopsy specimens in advanced rectal cancer as a marker for predicting the response to neoadjuvant treatment. We also investigated the correlation between the antitumor immune status after neoadjuvant treatment and the response to neoadjuvant treatment. In addition, we investigated the change in the local immune status before and after neoadjuvant treatment.
| MATERIALS AND METHODS

| Patients
Sixty-four patients with locally advanced rectal cancer were enrolled in this study. All patients underwent resection of rectal cancer after neoadjuvant treatment (neoadjuvant CT or CRT) at the Department of Surgical Oncology, Osaka City University (Osaka, Japan) between January 2010 and February 2017. The indication for neoadjuvant treatment was the depth clinically diagnosed as T3-T4, or a positive clinical diagnosis of lymph node metastasis. There were no patients who underwent emergency surgery for perforation/obstruction in this study. The resected specimens were pathologically classified according to the UICC TNM classification of malignant tumors (7th edition). 7 Chemotherapy was given alone or concomitantly with radiation as one or two cytotoxic agents based on fluoropyrimidine with or without a molecular-targeting drug. For CRT, patients received 50. 4 Gy in 28 fractions to the pelvis using 3-D conformal irradiation.
The tumor response was evaluated by pathologists according to the definitions in the Japanese Classification of Colorectal Carcinoma (8th edition): 15 
| Tissue microarray construction
A TMA with one 3.0-mm-diameter punch core per tumor was constructed from formalin-fixed paraffin-embedded tissue blocks of pretreatment biopsy specimens and post-treatment resected specimens, as previously reported. 16 We ensured that the specific histological type of cancer was representatively included in the TMA using H&E-stained TMA sections. 
| Immunohistochemical evaluation for MMR status
It was reported that the effectiveness of immunohistochemical evaluation of the MMR status is similar to that of genotyping for the MSI status. 17 The MSI status therefore was estimated according to the immunohistochemical evaluation of the MMR status, as previously reported. 18 Normal colon tissue was used as a positive control, and positive staining within intratumoral immune cells was used as an internal positive control. The expression was evaluated as MMR-proficient (tumor cell nuclear expression with positive immune cell expression; Figure 3A ,B,D,F) or MMR-deficient (absent tumor cell nuclear expression with positive immune cell expression; Figure 3C ,E,G). The tumor was defined as MMR-deficient when one or more MMR proteins was negatively expressed.
2.6 | Immunohistochemical evaluation for HLA class
I expression
We evaluated the HLA class I expression using the criteria established by the HLA and Cancer Component of the 12th International Histocompatibility Workshop. 19 The tumor was defined as negative 
| Statistical analyses
The significance of the correlations between the density of TILs and the response and those between the density of TILs and the clinicopathological characteristics were analyzed using the v 
| Ethical considerations
This study conformed to the provisions of the Declaration of Helsinki. All patients were informed of the investigational nature of this 3 | RESULTS
| Patient analysis
The patient characteristics are listed in Table 1 A low density of CD8 + and GATA3 + TILs in pretreatment biopsy samples was significantly associated with a poor pathological response (CD8, P < .001; GATA3, P = .011; Table 2 ). However, the density of all other TILs in pretreatment biopsy samples showed no significant relationship with the pathological response or downstaging of the primary tumor ( Table 2 ). The density of CD8 + TILs in pretreatment biopsy samples showed no significant relationship with any clinicopathological factors or the MMR status or pretreatment HLA class I expression (Table S1) .
A low density of CD8 + TILs at the invasive margin in post-treatment resected specimens was significantly associated with a poor pathological response (P < .001) and a low rate of downstaging of the primary tumor (P = .007; Table 3 ). A low density of T-bet + and
RORcT + TILs in post-treatment resected specimens was significantly associated with a low rate of downstaging of the primary tumor (Tbet, P < .001; RORcT, P = .032) (Table 3) . However, the density of all other TILs in post-treatment resected specimens showed no significant relationship with the pathological response or the downstaging of the primary tumor (Table 3) .
A high density of CD8 + TILs at the invasive margin in posttreatment resected specimens was significantly associated with a decrease in tumor depth (P = .005; Table S2 ). Furthermore, the density of CD8 + TILs in the post-treatment resected specimens was significantly associated with pathological lymph node metastases (P < .001), lymphatic involvement (P = .004), and the posttreatment serum carcinoembryonic antigen concentration (P = .002; Table S2 ). A one-to-one correspondence of CD8 + TILs was observed between pretreatment biopsy and post-treatment resected specimens ( Figure 5 ). In total patients and in responders, the density of CD8 + TILs at the surface of the tumor in post-treatment resected specimens was significantly higher than in the pretreatment biopsy specimens (all patients, P = .013; responders, P = .034) ( Figure 5A ,B). However, in non-responders, the density of CD8 + TILs in post-treatment resected specimens was not higher than in the pretreatment biopsy specimens (Figure 5C ).
| Analysis of neoadjuvant CT cohort
Patient characteristics are listed in Table 1 . The distribution of pretreatment clinical depth and lymph node metastasis of cancer was as follows: cT1-2 in 1 patient, cT3-4 in 32, cN0 in 3, and cN1-3 in 30.
The pathological response of the patients was as follows: grade 0, n = 4; grade 1a, n = 17; grade 1b, n = 8; grade 2, n = 3; and grade 3, n = 1. A low density of CD8 + TILs in pretreatment biopsy samples was significantly associated with a poor pathological response (CD8, P = .022; Table 4 ). However, the density of all other TILs in pretreatment biopsy samples showed no significant relationship with the pathological response or downstaging of the primary tumor (Table 4 ). The density of CD8 + TILs in pretreatment biopsy samples showed no significant relationship with any clinicopathological factors or the MMR status or pretreatment HLA class I expression (Table S3) .
A low density of CD8 + TILs at the invasive margin in posttreatment resected specimens was significantly associated with a poor pathological response (P < .001) ( Table 5) . A low density of Foxp3 + TILs in post-treatment resected specimens was significantly associated with a low rate of downstaging of the primary tumor (P = .024), and a low density of T-bet + TILs in post-treatment resected specimens tended to be associated with a low rate of downstaging of the primary tumor (P = .060; Table 5 ).
However, the density of all other TILs in post-treatment resected specimens showed no significant relationship with the pathological response or downstaging of the primary tumor (Table 5 ).
The density of CD8 + TILs at the invasive margin in post-treatment resected specimens showed no significant relationship with any clinicopathological factors or MMR status or pretreatment HLA class I expression (Table S4 ). In the total patient cohort, as well as in the responders and non-responders, the density of CD8 + TILs was not markedly changed after neoadjuvant chemotherapy ( Figure 6 ).
| Analysis of neoadjuvant CRT cohort
Patient characteristics are listed in Table 1 . The distribution of pretreatment clinical depth and lymph node metastasis of cancer was as follows: cT1-2 in no patients, cT3-4 in 31, cN0 in 15, and cN1-3 in 16. The pathological responses of the patients were: grade 0, n = 0; grade 1a, n = 8; grade 1b, n = 9; grade 2, n = 9; and grade 3, n = 5.
A low density of CD8 + TILs in pretreatment biopsy samples tended to be associated with a poor pathological response (P = .077; Table 5 ). However, the density of all other TILs in pretreatment biopsy samples showed no significant relationship with the pathological response or downstaging of the primary tumor ( Table 6 ). The density of CD8 + TILs in pretreatment biopsy samples showed no significant relationship with any clinicopathological factors or the MMR status or pretreatment HLA class I expression (Table S5) .
A low density of CD8 + TILs at the invasive margin in post-treatment resected specimens tended to be associated with a poor pathological response (P = .095) and a low rate of downstaging of the primary tumor (P = .057; Table 7 ). Furthermore, a low density of T-bet + TILs in post-treatment resected specimens was significantly associated with a low rate of downstaging of the primary tumor (P = .045; Table 7 ). However, the density of all other TILs in posttreatment resected specimens showed no significant relationship with the pathological response or downstaging of the primary tumor (Table 7 ).
The density of CD8 + TILs at the invasive margin in post-treatment resected specimens was significantly associated with lymph node metastases (P = .004) and the post-treatment serum carcinoembryonic antigen concentration (P = .026) (Table S6) . Furthermore, the high density of CD8 + TILs at the invasive margin in post-treatment resected specimens tended to be associated with a decrease in tumor depth (P = .057; Table S6 ).
In the total patient cohort as well as in the responders, the density of CD8 + TILs at the surface of the tumor in post-treatment resected specimens was significantly higher than in the pretreatment biopsy specimens (all patients, P = .003; responders, P = .024) (Figure 7A,B) . However, in the non-responders, the density of CD8 + TILs in post-treatment resected specimens was not higher than in the pretreatment biopsy specimens ( Figure 7C ).
| DISCUSSION
The current study showed that the local antitumor immune status before and after neoadjuvant therapy was significantly associated with the response to neoadjuvant therapy. Furthermore, we showed that neoadjuvant therapy, especially CRT, might activate local antitumor immunity.
The current study suggests that tumors attracting abundant According to the definitions in the Japanese Classification of Colorectal Carcinoma (8th edition). neoadjuvant CRT. Our results agreed with those of previous studies. [11] [12] [13] 20 Our results were also supported by the basic research studies that have shown that CT or radiotherapy is more effective in immunocompetent mice than in immunodeficient mice and that immunosuppression counteracts the effect of CRT. 21, 22 The attraction of increased numbers of TILs before neoadjuvant treatment was reported to imply that a tumor was originally immunogenic. 20 For tumors attracting large numbers of TILs before neoadjuvant treatment, it is considered that not only the direct cytotoxic effects of CT or radiotherapy but also the antitumor immune response of the host will improve the effects of the treatment.
The current study showed that the density of CD8 + TILs after neoadjuvant CT or CRT positively correlated with the efficacy of the neoadjuvant treatment, such as the pathological response and downstaging of the primary tumor. Cytotoxic agents and radiation have been reported to be extremely effective as treatments, not only because they exert direct cytotoxic effects on tumor cells, but also because they activate the antitumor immune response. to activate CD8 + T cells and enhance antitumor immunity. 4, 26, 27 This fact supports our finding that a high density of T-bet + TILs after neoadjuvant therapy was positively correlated with a high rate of downstaging of the primary tumor. In contrast, Th2 cells,
Correlations between the density of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsy specimens and response to neoadjuvant treatment in 64 patients with locally advanced rectal cancer Foxp3, forkhead box P3; GATA3, GATA-binding protein 3; RORcT, RAR-related orphan receptor-cT; T-bet, t-box expressed in T cells. through the activation of B cells or the production of the immunosuppressive cytokine interleukin-10, seem to suppress the antitumor immunity. 4 Regarding Th17 cells, some authors have reported that these cells facilitate the antitumor immunity, whereas others have reported that they accelerate tumor growth through neoangiogenesis of the tumor. 4, 26 In colorectal cancer, the significance of T A B L E 3 Correlations between the density of tumor-infiltrating lymphocytes (TILs) in post-treatment resected specimens and response to neoadjuvant treatment in 64 patients with locally advanced rectal cancer Foxp3, forkhead box P3; GATA3, GATA-binding protein 3; RORcT, RAR-related orphan receptor-cT; T-bet, t-box expressed in T cells. | 973
Foxp3
+ TILs seems to be controversial. We found in the present study that the density of Foxp3 + TILs after neoadjuvant chemotherapy was positively associated with downstaging of the primary tumor, although the density of Foxp3 + TILs before and after neoadjuvant chemotherapy was not associated with the pathological response to treatment. Regulatory T cells, which express the transcription factor Foxp3, suppress the activation of T cells. A high density of Foxp3 + TILs was reported to be associated with poor prognosis in several types of cancer. 28, 29 In contrast, in colorectal cancer, a previous study with a large cohort showed that a high density of Foxp3 + TILs was associated with a good prognosis. 30 Furthermore, another recent study suggested that two Foxp3 + T-cell subsets (immunosuppressive Foxp3 + Treg cells and non-suppressive Foxp3 + T cells) distinctly control the prognosis of colorectal cancer. 31 The association between the density of Foxp3 + TILs and the response to neoadjuvant therapy also remains unclear, with conflicting findings reported. Indeed, some reports have found that a low density of Foxp3 + TILs after neoadjuvant CRT for rectal cancer was associated with a complete response, 32 whereas others have found that the density of Foxp3 + TILs before and after neoadjuvant therapy for rectal cancer was not associated with the response to treatment.
11,33
The findings obtained in the current study suggest that local antitumor immunity could be enhanced by increased numbers of CD8 + TILs after neoadjuvant therapy, especially in responders.
Cytotoxic agents and radiation have been previously reported to be immunosuppressants because lymphocytes are very sensitive to cytotoxic agents and radiation. 34 However, another aspect to the effects of cytotoxic agents and radiation was recently reported, involving their effects on enhancing the antitumor immunity and thereby contributing to their direct antitumor effects. 23, 24 Both CTand radiotherapy-mediated necrotic tumor cell death were reported to induce the release of tumor antigens and facilitate the recruitment of immune cells to the tumor by mediators such as proinflammatory cytokine interferon-c. 35 In this way, CT and radiotherapy have been reported to enhance antitumor immunity. 35 In addition, cytotoxic agents and radiation also enhance antitumor immunity through other mechanisms. For example, 5-fluorouracil was reported to prevent immunosuppression by reducing the numbers of myeloid-derived suppressor cells and promoting the production of interferon-c. 36 Oxaliplatin was reported to induce immunogenic cancer cell death and result in the activation of the immune response of T cells. 37 Radiation was further reported to activate the antitumor immune response through cancer cell death and inducing the abscopal effect. 38 Furthermore, recent reports have shown that anti-epidermal growth factor receptor antibody might increase the density of CD3 + and CD8 + TILs and enhance the antitumor immune response by inducing antibody-dependent
Correlations between the density of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsy specimens and response to treatment in the neoadjuvant chemotherapy cohort of patients with locally advanced rectal cancer (n = 33) cell-mediated cytotoxicity through immune cells and immunogenic cell death. 39, 40 As described above, many previous reports have
shown that CT and radiotherapy can induce the activation of the antitumor immune response. The subgroup analysis in the current study showed that the density of CD8 + TILs after neoadjuvant CT was not increased, whereas that after neoadjuvant CRT was notably T A B L E 5 Correlations between the density of tumor-infiltrating lymphocytes (TILs) in post-treatment resected specimens and response to treatment in the neoadjuvant chemotherapy cohort of patients with locally advanced rectal cancer (n = 33) Foxp3, forkhead box P3; GATA3, GATA-binding protein 3; RORcT, RAR-related orphan receptor-cT; T-bet, t-box expressed in T cells. T A B L E 6 No statistically significant correlation between the density of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsy specimens and response to treatment in the neoadjuvant chemoradiotherapy cohort of patients with locally advanced rectal cancer (n = 31) Foxp3, forkhead box P3; GATA3, GATA-binding protein 3; RORcT, RAR-related orphan receptor-cT; T-bet, t-box expressed in T cells. T A B L E 7 Correlations between the density of tumor-infiltrating lymphocytes (TILs) in post-treatment resected specimens and response to treatment in the neoadjuvant chemoradiotherapy cohort of patients with locally advanced rectal cancer (n = 31) Foxp3, forkhead box P3; GATA3, GATA-binding protein 3; RORcT, RAR-related orphan receptor-cT; T-bet, t-box expressed in T cells. 
